Analysis of hiPSCs differentiation toward hepatocyte-like cells upon extended exposition to oncostatin

Differentiation. 2020 Jul-Aug:114:36-48. doi: 10.1016/j.diff.2020.05.006. Epub 2020 May 19.

Abstract

The capability to produce and maintain functional human adult hepatocytes remains one of the major challenges for the use of in-vitro models toward liver cell therapy and industrial drug-screening applications. Among the suggested strategies to solve this issue, the use of human-induced pluripotent stem cells (hiPSCs), differentiated toward hepatocyte-like cells (HLCs) is promising. In this work, we propose a 31-day long protocol, that includes a final 14-day long phase of oncostatin treatment, as opposed to a 7-day treatment which led to the formation of a hepatic tissue functional for CYP1A2, CYP2B6, CYP2C8, CYP2D6, and CYP3A4. The production of albumin, as well as bile acid metabolism and transport, were also detected. Transcriptome profile comparisons and liver transcription factors (TFs) motif dynamics revealed increased expression of typical hepatic markers such as HNF1A and of important metabolic markers like PPARA. The performed analysis has allowed for the extraction of potential targets and pathways which would allow enhanced hepatic maturation in-vitro. From this investigation, NRF1 and SP3 appeared as transcription factors of importance. Complex epithelial-mesenchymal transition (EMT) and mesenchymal-epithelial transition (MET) patterns were also observed during the differentiation process. Moreover, whole transcriptome analysis highlighted a response typical of the one observed in liver regeneration and hepatocyte proliferation. While a complete maturation of hepatocytes was yet to be obtained, the results presented in this work provide new insights into the process of liver development and highlight potential targets aimed to improve in-vitro liver regeneration.

Keywords: Differentiation; Hepatocytes; Induced pluripotent stem cells; nanoCAGE.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cell Differentiation / drug effects
  • Cell Differentiation / genetics*
  • Cell Proliferation / drug effects
  • Cytochrome P-450 CYP1A2 / genetics
  • Cytochrome P-450 CYP2B6 / genetics
  • Cytochrome P-450 CYP2C8 / genetics
  • Cytochrome P-450 CYP2D6 / genetics
  • Cytochrome P-450 CYP3A / genetics
  • Drug Evaluation, Preclinical
  • Epithelial-Mesenchymal Transition / drug effects
  • Hepatocytes / cytology*
  • Hepatocytes / metabolism
  • Humans
  • Induced Pluripotent Stem Cells / cytology*
  • Induced Pluripotent Stem Cells / metabolism
  • Liver / cytology
  • Liver / drug effects
  • Liver / growth & development*
  • Liver Regeneration*
  • Nuclear Respiratory Factor 1 / genetics
  • Oncostatin M / pharmacology
  • Sp3 Transcription Factor / genetics
  • Transcriptome / drug effects

Substances

  • NRF1 protein, human
  • Nuclear Respiratory Factor 1
  • SP3 protein, human
  • Oncostatin M
  • Sp3 Transcription Factor
  • Cytochrome P-450 CYP1A2
  • Cytochrome P-450 CYP2B6
  • Cytochrome P-450 CYP2C8
  • Cytochrome P-450 CYP2D6
  • Cytochrome P-450 CYP3A